Cargando…

Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907

Detalles Bibliográficos
Autores principales:	Østergaard, Helena Bleken, van der Leeuw, Joep, Visseren, Frank L.J., Westerink, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2021
Materias:	e-Letters: Comments and Responses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247492/ https://www.ncbi.nlm.nih.gov/pubmed/34016608 http://dx.doi.org/10.2337/dc21-0364

Ejemplares similares

Response to Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907
por: Vistisen, Dorte, et al.
Publicado: (2021)

Comment on Lachin et al. The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. Diabetes Care 2021;44:2225–2230
por: Quinn, Lauren M., et al.
Publicado: (2022)

Comment on Dawed et al. Genome-Wide Meta-Analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673–2682
por: Wang, Ke, et al.
Publicado: (2022)

Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673–2682
por: Dawed, Adem Y., et al.
Publicado: (2022)

Comment on Lee et al. Multicenter, Head-to-Head, Real-World Validation Study of Seven Automated Artificial Intelligence Diabetic Retinopathy Screening Systems. Diabetes Care 2021;44:1168–1175
por: Soliz, Peter
Publicado: (2021)

Response to Comment on Gregory et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic’s Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526–532
por: Gregory, Justin M., et al.
Publicado: (2021)

Comment on Albogami et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344–1352
por: Foer, Dinah, et al.
Publicado: (2021)

Response to Comment on Lee et al. Multicenter, Head-to-Head, Real-World Validation Study of Seven Automated Artificial Intelligence Diabetic Retinopathy Screening Systems. Diabetes Care 2021;44:1168–1175
por: Lee, Aaron Y., et al.
Publicado: (2021)

Comment on Menke et al. Metals in Urine and Diabetes in U.S. Adults. Diabetes 2016;65:164–171
por: Wong, Winifred P., et al.
Publicado: (2016)

Response to Comment on Malik. Which Test for Diagnosing Early Human Diabetic Neuropathy? Diabetes 2014;63:2206–2208
por: Petropoulos, Ioannis N., et al.
Publicado: (2015)

Comment on Löndahl. Number Eight in the Service of Diabetic Foot Ulcer Healing. Diabetes Care 2020;43:515–517
por: Frykberg, Robert G.
Publicado: (2020)

Comment on Young-Hyman et al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Mezuk, Briana, et al.
Publicado: (2017)

Response to Comment on Young-Hyman et al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Young-Hyman, Deborah, et al.
Publicado: (2018)

Response to Comments on Young-Hyman et al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
por: Young-Hyman, Deborah, et al.
Publicado: (2017)

Comment on Moore et al. Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. Diabetes Care 2013;36:2981–2987
por: Goodarzi, Mark O.
Publicado: (2014)

Response to Comment on Jaiswal et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care 2017;40:1226–1232
por: Jaiswal, Mamta, et al.
Publicado: (2018)

Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes—2016. Diabetes Care 2016;39(Suppl. 1):S52–S59
por: Herman, William H., et al.
Publicado: (2016)

Comment on Mizokami-Stout et al. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. Diabetes Care 2020;43:806–812
por: Kostev, Karel
Publicado: (2020)

Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777–783
por: Lachin, John M., et al.
Publicado: (2017)

Response to Comment on Mizokami-Stout et al. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. Diabetes Care 2020;43:806–812
por: Mizokami-Stout, Kara R., et al.
Publicado: (2020)

Response to Comment on Cefalu et al. The Alarming and Rising Costs of Diabetes and Prediabetes: A Call for Action! Diabetes Care 2014;37:3137–3138
por: Cefalu, William T., et al.
Publicado: (2015)

Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508
por: Home, Philip, et al.
Publicado: (2014)

Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684–1692
por: Inzucchi, Silvio E., et al.
Publicado: (2017)

Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care 2019;42:258–264
por: Sims, Emily K., et al.
Publicado: (2019)

Response to Comment on Vassy et al. Polygenic Type 2 Diabetes Prediction at the Limit of Common Variant Detection. Diabetes 2014;63:2172–2182
por: Vassy, Jason L., et al.
Publicado: (2014)

Response to Comment on Lontchi-Yimagou et al. An Atypical Form of Diabetes Among Individuals With Low BMI. Diabetes Care 2022;45:1428–1437
por: Lontchi-Yimagou, Eric, et al.
Publicado: (2022)

Comment on Duarte et al. Systematic Review and Network Meta-analysis of Neurostimulation for Painful Diabetic Neuropathy. Diabetes Care 2022;45:2466–2475
por: Sharan, Ashwini D., et al.
Publicado: (2023)

Comment on Skudder-Hill et al. Fat Distribution Within the Pancreas According to Diabetes Status and Insulin Traits. Diabetes 2022;71:1182–1192
por: Yang, Jie, et al.
Publicado: (2022)

Response to Comment on Piccinini and Bergman The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
por: Bergman, Richard N., et al.
Publicado: (2021)

Response to Comment on Laiteerapong et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care 2019;42:416–426
por: Laiteerapong, Neda, et al.
Publicado: (2019)

Comment on Bonnet et al. Association Between Handedness and Type 2 Diabetes: The E3N Study. Diabetes Care 2015;38:e199
por: Selvin, Elizabeth
Publicado: (2016)

Comment on Vimalananda et al. Depressive Symptoms, Antidepressant Use, and the Incidence of Diabetes in the Black Women’s Health Study. Diabetes Care 2014;37:2211–2217
por: Kivimäki, Mika, et al.
Publicado: (2015)

Response to Comment on Hedderson et al. Prepregnancy SHBG Concentrations and Risk for Subsequently Developing Gestational Diabetes Mellitus. Diabetes Care 2014;37:1296–1303
por: Hedderson, Monique M., et al.
Publicado: (2014)

Response to Comment on Lacy et al. Long-term Glycemic Control and Dementia Risk in Type 1 Diabetes. Diabetes Care 2018;41:2339–2345
por: Lacy, Mary E., et al.
Publicado: (2019)

Comment on Hsu et al. BMI Cut Points to Identify At-Risk Asian Americans for Type 2 Diabetes Screening. Diabetes Care 2015;38:150–158
por: Yi, Stella S., et al.
Publicado: (2015)

Comment on Sofi et al. pH of Drinking Water Influences the Composition of Gut Microbiome and Type 1 Diabetes Incidence. Diabetes 2014;63:632–644
por: Zhao, Yongge, et al.
Publicado: (2015)

Comment on Chen et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care 2020;43:1399–1407
por: Cariou, Bertrand, et al.
Publicado: (2020)

Comment on Koivusalo et al. Gestational Diabetes Mellitus Can Be Prevented by Lifestyle Intervention: The Finnish Gestational Diabetes Prevention Study (RADIEL): A Randomized Controlled Trial. Diabetes Care 2016;39:24–30
por: Bao, Wei
Publicado: (2016)

Comment on Davis et al. Development and Validation of a Simple Hip Fracture Risk Prediction Tool for Type 2 Diabetes: The Fremantle Diabetes Study Phase I. Diabetes Care 2018;42:102–109
por: Bůžková, Petra, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rdb3k7nubvc7m9a71fc2h1r04c